23andMe Paves the Way for Direct-to-Consumer Genetic Health Risk Tests of Limited Clinical Utility

This commentary discusses the limited clinical utility of 23andMe's direct-to-consumer (DTC) genetic test and raises concerns that its approval creates a pathway that could lead to expansive DTC genetic testing of similarly low clinical utility that the public will misunderstand and misuse.

http://ift.tt/2sf5UQv